Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immatics NV (IMTX)

Immatics NV (IMTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,256,827
  • Shares Outstanding, K 121,550
  • Annual Sales, $ 168,630 K
  • Annual Income, $ 16,470 K
  • EBIT $ -161 M
  • EBITDA $ -147 M
  • 60-Month Beta 1.36
  • Price/Sales 7.13
  • Price/Cash Flow 40.48
  • Price/Book 2.47

Options Overview Details

View History
  • Implied Volatility 182.98% (-32.24%)
  • Historical Volatility 80.86%
  • IV Percentile 73%
  • IV Rank 31.98%
  • IV High 509.94% on 11/07/25
  • IV Low 29.28% on 09/09/25
  • Expected Move (DTE 15) 0.64 (5.37%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 91
  • Volume Avg (30-Day) 44
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 18,487
  • Open Int (30-Day) 18,506
  • Expected Range 11.23 to 12.51

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.48
  • Number of Estimates 1
  • High Estimate -0.48
  • Low Estimate -0.48
  • Prior Year 0.48
  • Growth Rate Est. (year over year) -200.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.69 +36.59%
on 11/07/25
12.41 -4.35%
on 12/04/25
+2.62 (+28.32%)
since 11/04/25
3-Month
5.67 +109.35%
on 09/16/25
12.41 -4.35%
on 12/04/25
+6.15 (+107.52%)
since 09/04/25
52-Week
3.30 +259.70%
on 04/07/25
12.41 -4.35%
on 12/04/25
+3.90 (+48.93%)
since 12/04/24

Most Recent Stories

More News
Immatics: Q3 Earnings Snapshot

Immatics: Q3 Earnings Snapshot

IMTX : 11.87 (+14.80%)
Immatics: Q2 Earnings Snapshot

Immatics: Q2 Earnings Snapshot

IMTX : 11.87 (+14.80%)
Immatics: Q1 Earnings Snapshot

Immatics: Q1 Earnings Snapshot

IMTX : 11.87 (+14.80%)
Private Sector Steps Up in Cancer Research as Federal Support Wavers

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As the Trump administration signals potential cuts to the National Institutes of Health (NIH), questions...

ONCY : 0.9807 (+8.19%)
SMMT : 18.81 (+2.40%)
CADL : 5.26 (+4.78%)
IMTX : 11.87 (+14.80%)
EXEL : 44.37 (+0.82%)
ONC.TO : 1.42 (+2.16%)
New Strong Buy Stocks for February 12th

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Bank of Hawaii Corporation BOH: This bank holding company for Bank of Hawaii has seen the Zacks Consensus Estimate for its current...

RH : 159.94 (-1.46%)
BHRB : 66.93 (+0.03%)
BOH : 66.62 (+0.95%)
IMTX : 11.87 (+14.80%)
AUB : 34.98 (unch)
Immatics N.V. Reports Promising Clinical Data for TCR Bispecific Molecules and Advances Four Cancer Therapy Candidates

Immatics targets five cancer types with TCR-T therapies; recent data shows promising results for TCER® IMA402 and ACTengine® IMA203.Quiver AI SummaryImmatics N.V. announced a strategic expansion of its...

IMTX : 11.87 (+14.80%)
Immatics: Q3 Earnings Snapshot

Immatics: Q3 Earnings Snapshot

IMTX : 11.87 (+14.80%)
Immatics: Q2 Earnings Snapshot

Immatics: Q2 Earnings Snapshot

IMTX : 11.87 (+14.80%)
Immatics: Q1 Earnings Snapshot

Immatics: Q1 Earnings Snapshot

IMTX : 11.87 (+14.80%)
Immatics: Q3 Earnings Snapshot

Immatics: Q3 Earnings Snapshot

IMTX : 11.87 (+14.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Immatics N.V. engages in the discovery of targets for cancer immunotherapies. It is developing targeted immunotherapies with focus on treating solid tumors. Immatics N.V., formerly known as ARYA SCIENCES, is based in Tuebingen, Germany.

See More

Key Turning Points

3rd Resistance Point 15.29
2nd Resistance Point 13.85
1st Resistance Point 12.86
Last Price 11.87
1st Support Level 10.43
2nd Support Level 8.99
3rd Support Level 8.00

See More

52-Week High 12.41
Last Price 11.87
Fibonacci 61.8% 8.93
Fibonacci 50% 7.86
Fibonacci 38.2% 6.78
52-Week Low 3.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar